Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia
The BCL2 inhibitor venetoclax has recently been approved for the treatment of older patients with acute myeloid leukemia. Real-world experience with this drug is important to validate the activity of this agent and was explored by Pollyea and colleagues, who compared outcomes of patients treated with venetoclax and azacytidine to a cohort of patients treated on a clinical trial.
Cold agglutinin disease is a rare hemolytic anemia that is poorly understood. Berentsen and colleagues utilized the Danish National Patient Registry to identify its incidence, risk of thromboembolic events, and mortality compared to a matched cohort.
Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis
Novel drugs and autologous transplantation are part of the reasons why overall outcomes for patients with multiple myeloma continue to improve. Ailawadhi and colleagues explored racial disparities in treatment patterns in a report with sobering findings.
The vascular complications of sickle cell disease are well recognized and of great clinical importance. In a review article, Nasimuzzaman and Malik discuss the role of the coagulation system in sickle cell disease pathogenesis. We hope you find this comprehensive review useful and informative.
Megakaryocytes package contents into separate α-granules that are differentially distributed in platelets
A number of important biological functions have been attributed to platelets ranging from hemostasis to inflammation. Many of these functions are impacted by distinct proteins targeted in α-granules. In an interesting study, Italiano Jr. and colleagues explored the differential packaging of discrete bioactive contents during megakaryocyte differentiation into platelets to help explain this fascinating biology.
Allogeneic hematopoietic cell transplantation has been a highly successful therapy for the treatment of patients with severe aplastic anemia. Eapen and colleagues analyzed a large number of patients to explore the preparative regimen for optimal outcomes.